Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission

Kofi Clarke, Miguel Regueiro

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

The emergence of biologic response modifiers and earlier use of immunomodulators for inflammatory bowel disease (IBD) patients have improved outcomes. Durable remissions have been achieved in many IBD patients on these treatments, but the duration of treatment and identifying which patients may stop therapy is yet unresolved. Recently, the term very deep remission (defined as clinical remission [CDAI < 150] and endoscopic remission) has been applied to patients on immunomodulators/biologics who have no clinical symptoms or objective signs of inflammatory disease. Whether or not patients who achieve and maintain a very deep remission may successfully stop treatment is not known. This article will review the current data on stopping treatment in IBD and identify certain factors that are associated with a high relapse rate after discontinuing treatment. Where evidence-based data are lacking, the authors provide their opinion.

Original languageEnglish (US)
Pages (from-to)174-179
Number of pages6
JournalInflammatory Bowel Diseases
Volume18
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Immunologic Factors
Biological Products
Inflammatory Bowel Diseases
Therapeutics
Recurrence

All Science Journal Classification (ASJC) codes

  • Gastroenterology
  • Immunology and Allergy

Cite this

@article{67946d82bca448ce9b93c67414b36bbd,
title = "Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission",
abstract = "The emergence of biologic response modifiers and earlier use of immunomodulators for inflammatory bowel disease (IBD) patients have improved outcomes. Durable remissions have been achieved in many IBD patients on these treatments, but the duration of treatment and identifying which patients may stop therapy is yet unresolved. Recently, the term very deep remission (defined as clinical remission [CDAI < 150] and endoscopic remission) has been applied to patients on immunomodulators/biologics who have no clinical symptoms or objective signs of inflammatory disease. Whether or not patients who achieve and maintain a very deep remission may successfully stop treatment is not known. This article will review the current data on stopping treatment in IBD and identify certain factors that are associated with a high relapse rate after discontinuing treatment. Where evidence-based data are lacking, the authors provide their opinion.",
author = "Kofi Clarke and Miguel Regueiro",
year = "2012",
month = "1",
doi = "10.1002/ibd.21792",
language = "English (US)",
volume = "18",
pages = "174--179",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. / Clarke, Kofi; Regueiro, Miguel.

In: Inflammatory Bowel Diseases, Vol. 18, No. 1, 01.2012, p. 174-179.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission

AU - Clarke, Kofi

AU - Regueiro, Miguel

PY - 2012/1

Y1 - 2012/1

N2 - The emergence of biologic response modifiers and earlier use of immunomodulators for inflammatory bowel disease (IBD) patients have improved outcomes. Durable remissions have been achieved in many IBD patients on these treatments, but the duration of treatment and identifying which patients may stop therapy is yet unresolved. Recently, the term very deep remission (defined as clinical remission [CDAI < 150] and endoscopic remission) has been applied to patients on immunomodulators/biologics who have no clinical symptoms or objective signs of inflammatory disease. Whether or not patients who achieve and maintain a very deep remission may successfully stop treatment is not known. This article will review the current data on stopping treatment in IBD and identify certain factors that are associated with a high relapse rate after discontinuing treatment. Where evidence-based data are lacking, the authors provide their opinion.

AB - The emergence of biologic response modifiers and earlier use of immunomodulators for inflammatory bowel disease (IBD) patients have improved outcomes. Durable remissions have been achieved in many IBD patients on these treatments, but the duration of treatment and identifying which patients may stop therapy is yet unresolved. Recently, the term very deep remission (defined as clinical remission [CDAI < 150] and endoscopic remission) has been applied to patients on immunomodulators/biologics who have no clinical symptoms or objective signs of inflammatory disease. Whether or not patients who achieve and maintain a very deep remission may successfully stop treatment is not known. This article will review the current data on stopping treatment in IBD and identify certain factors that are associated with a high relapse rate after discontinuing treatment. Where evidence-based data are lacking, the authors provide their opinion.

UR - http://www.scopus.com/inward/record.url?scp=83555174451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83555174451&partnerID=8YFLogxK

U2 - 10.1002/ibd.21792

DO - 10.1002/ibd.21792

M3 - Review article

C2 - 21674731

AN - SCOPUS:83555174451

VL - 18

SP - 174

EP - 179

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 1

ER -